Schizophrenia polygenic risk scores in youth mental health: preliminary associations with diagnosis, clinical stage and functioning. Issue 2 (22nd February 2021)

• Record Type: Journal Article
• Authors: Crouse, Jacob J.; Carpenter, Joanne S.; Iorfino, Frank; Lin, Tian; Ho, Nicholas; Byrne, Enda M.; Henders, Anjali K.; Wallace, Leanne; Hermens, Daniel F.; Scott, Elizabeth M.; Wray, Naomi R.; Hickie, Ian B.
• Is Part Of: BJPsych open. Volume 7:Issue 2(2021)
• Publication Date: 2021-02-22
• Subjects: Genetics, -- youth mental health, -- psychiatry, -- early intervention, -- transdiagnostic; Psychiatry -- Periodicals; Mental health -- Periodicals; 616.89005
• DOI: 10.1192/bjo.2021.14
• Languages: English
• ISSNs: 2056-4724

Abstract

Abstract : Background: The schizophrenia polygenic risk score (SCZ-PRS) is an emerging tool in psychiatry. Aims: We aimed to evaluate the utility of SCZ-PRS in a young, transdiagnostic, clinical cohort. Method: SCZ-PRSs were calculated for young people who presented to early-intervention youth mental health clinics, including 158 patients of European ancestry, 113 of whom had longitudinal outcome data. We examined associations between SCZ-PRS and diagnosis, clinical stage and functioning at initial assessment, and new-onset psychotic disorder, clinical stage transition and functional course over time in contact with services. Results: Compared with a control group, patients had elevated PRSs for schizophrenia, bipolar disorder and depression, but not for any non-psychiatric phenotype (for example cardiovascular disease). Higher SCZ-PRSs were elevated in participants with psychotic, bipolar, depressive, anxiety and other disorders. At initial assessment, overall SCZ-PRSs were associated with psychotic disorder (odds ratio (OR) per s.d. increase in SCZ-PRS was 1.68, 95% CI 1.08–2.59, P = 0.020), but not assignment as clinical stage 2+ (i.e. discrete, persistent or recurrent disorder) (OR = 0.90, 95% CI 0.64–1.26, P = 0.53) or functioning ( R = 0.03, P = 0.76). Longitudinally, overall SCZ-PRSs were not significantly associated with new-onset psychotic disorder (OR = 0.84, 95% CI 0.34–2.03, P = 0.69), clinical stage transition (OR = 1.02, 95% CI 0.70–1.48, P = 0.92) or persistent functional impairment (OR = 0.84, 95% CI 0.52–1.38, P = 0.50). Conclusions: In this preliminary study, SCZ-PRSs were associated with psychotic disorder at initial assessment in a young, transdiagnostic, clinical cohort accessing early-intervention services. Larger clinical studies are needed to further evaluate the clinical utility of SCZ-PRSs, especially among individuals with high SCZ-PRS burden.